Drug intelligence / Profile preview

AE002

Development stage: Preclinical
Lead developer: ActualEyes
Modality: Small Molecules
Administration: Topical, Ophthalmic

Overview

AE002 is a small molecule ophthalmic solution being developed by ActualEyes for the treatment of Fuchs endothelial corneal dystrophy (FECD). Currently in the preclinical development stage, AE002 is designed to prevent the progression of FECD through a mechanism of action that is distinct from the company's lead candidate, AE001 (sirolimus). The therapy originated from research at Doshisha University aimed at elucidating the pathophysiology of corneal endothelial diseases and screening for effective drug candidates. It is intended for topical administration as eye drops.

Beyond the preview

Go deeper on AE002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AE002.

Explore the full profile